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Abstract	
Standard	therapy	of	patients	with	B-cell	non-Hodgkin	lymphoma	(B-NHL)	mostly	consists	of	
chemotherapy	combined	with	anti-CD20	(e.g.	rituximab)	immunotherapy.	However,	relapse	
of	 aggressive	 B-NHL	 occurs	 frequently,	 which	 may	 coincide	 with	 therapy	 resistance.	 This	
demonstrates	 the	 urgent	 need	 for	 exploring	 new	 lymphoma-targeted	 therapies.	 Here,	we	
review	 recent	 insights	 in	 the	 pathophysiology	 of	 B-NHL,	 and	 discuss	 CD20	 and	 three	
alternative	membrane	targets	(B-cell	receptor,	immune	checkpoints	PD-1/PD-L1,	tetraspanin	
CD37)	that	are	currently	in	the	spotlight	for	treatment	of	B-NHL.	Furthermore,	we	present	a	
novel	concept	in	which	plasma	membrane	organization	of	the	lymphoma	B	cell	determines	
the	 efficacy	 of	 membrane-targeted	 therapies,	 which	 has	 consequences	 for	 treatment	
application	and	clinical	outcome	for	patients	with	B-cell	lymphoma.	
	
Origin	of	B-cell	non-Hodgkin	lymphoma	
B	cells	undergo	several	distinct	phases	of	development,	starting	from	pre-B	cells	in	the	bone	
marrow	 towards	 ultimately	 the	 differentiation	 into	 antibody-producing	 plasma	 cells	 and	
memory	B	cells.	Upon	encountering	specific	antigens,	germinal	centers	(GC,	see	Glossary)	are	
formed	within	 the	 lymph	 node,	where	 B	 cells	 undergo	 somatic	 hypermutation	 (SHM,	 see	
Glossary)	 and	 class	 switch	 recombination	 (CSR,	 see	 Glossary)	 in	 order	 to	 generate	 a	 high	
affinity	B-cell	receptor	(BCR).	However,	SHM	and	CSR	are	error-prone	mechanisms,	hence	the	
majority	 of	 B-cell	 non-Hodgkin	 lymphomas	 (B-NHL)	 arises	 from	 GC	 B	 cells	 [1].	 These	 GC-
derived	B-cell	lymphomas	frequently	harbor	chromosomal	translocations	of	proto-oncogenes,	
like	BCL2,	BCL6	or	MYC,	that	are	relocated	under	the	control	of	the	active	immunoglobulin	
heavy	chain	(IGH)	locus	[1,2].	Since	these	translocations	often	involve	the	non-productively	
rearranged	IG	loci,	most	lymphomas	still	express	a	functional	BCR	[1].	
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The	 GC-derived	 B-NHLs	 include	 follicular	 lymphoma	 (FL,	 see	 Glossary),	 Burkitt	
lymphoma	(BL,	see	Glossary),	and	diffuse	large	B-cell	lymphoma	(DLBCL,	see	Glossary).	DLBCL	
is	 the	most	 prevalent	 type,	 accounting	 for	 approximately	 one	 third	 of	 all	 NHL	 cases.	 Two	
subtypes	of	DLBCL	have	been	identified:	germinal	center	B-cell-like	(GCB-)DLBCL,	arising	from	
GC	B	cells,	and	activated	B-cell-like	(ABC-)DLBCL,	which	has	a	post-GC	origin	[3].	ABC-DLBCL	is	
characterized	by	constitutively	active	BCR/NF-κB	signaling	[4],	and	has	a	worse	prognosis	than	
GCB-DLBCL	[3].	The	hallmark	of	BL	is	translocation	of	MYC	to	the	IGH	locus	[5].	Both	DLBCL	
and	BL	are	aggressive	cancers	in	contrast	to	FL,	which	is	an	indolent	lymphoma.	However,	in	a	
large	 proportion	 of	 FL	 cases	 the	 disease	 transforms	 into	 the	 more	 aggressive	 DLBCL	 [6].	
Current	 first-line	 treatment	 of	 DLBCL	 consists	 of	 the	 combination	 of	 rituximab	 (anti-CD20	
monoclonal	 antibody	 (mAb))	 with	 CHOP-based	 (see	 Glossary)	 chemotherapy,	 frequently	
followed	 by	 subsequent	 radiotherapy.	 BL	 is	 treated	 with	 CHOP-based	 chemotherapy,	
sometimes	combined	with	rituximab.	For	FL,	a	watch-and-wait	policy	is	frequently	applied.	In	
case	of	treatment	indication,	first-line	treatment	consists	of	rituximab	combined	with	CHOP-	
or	CVP-based	 (see	Glossary)	 chemotherapy	with	or	without	 subsequent	 radiotherapy.	 The	
exact	protocol	depends	on	the	diagnosis	and	condition	of	the	patient	[7–9].	
Although	 immunotherapy	 with	 rituximab	 has	 significantly	 improved	 the	 clinical	
outcome	of	patients	with	B-cell	malignancies	[10,11],	many	patients	with	DLBCL	[12],	BL	[11]	
and	 FL	 [13]	 suffer	 from	 treatment	 failure	 or	 relapse.	 Several	 novel	 targeted	 therapies	 are	
currently	 under	 (pre-)clinical	 investigation,	 including	 therapies	 targeting	 the	 tumor	
microenvironment	 (reviewed	 in	 [14]),	 and	 therapies	 targeting	 the	 lymphoma	cells	directly,	
either	intracellular	or	at	the	membrane	(reviewed	in	[15]).	Targeting	membrane	proteins	to	
treat	cancer	has	been	extensively	studied	by	researchers	and	clinicians	in	the	last	two	decades	
since	the	cell	surface	is	the	easiest	accessible	part	of	the	cell.	Rituximab	is	a	clear	example	of	
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successful	 antibody-based	 immunotherapy	 targeting	 a	membrane	protein.	 Antibody-based	
membrane-targeted	therapies	act	through	different	mechanisms,	including	direct	cell	death	
signaling,	 antibody-dependent	 cell-mediated	 cytotoxicity	 (ADCC,	 see	 Glossary)	 and	
complement-dependent	cytotoxicity	(CDC,	see	Glossary).	In	this	review,	we	focus	on	recent	
developments	 and	 new	 membrane-targeted	 therapies	 for	 GC-derived	 B-cell	 lymphoma	
(Figure	1a).	Furthermore,	we	propose	a	model	 illustrating	the	dynamic	cell	 surface	protein	
landscape	of	lymphoma	B	cells	that	influences	the	efficacy	of	membrane-targeted	therapies	
in	B-NHL.		
	
CD20	as	the	first	B-cell-specific	membrane	target	to	treat	B-NHL	
Anti-CD20	mAb	rituximab	represents	the	first	mAb	approved	for	cancer	therapy	by	the	FDA	in	
1997.	CD20	is	a	four-transmembrane	protein	expressed	on	mature	B	cells	that	is	involved	in	
B-cell	 activation	 and	 differentiation,	 mainly	 by	 controlling	 calcium	 influx	 [16].	 CD20	 was	
selected	in	the	early	1980’s	as	new	target	for	B-NHL	since	the	majority	of	B-NHL	cells	(90%)	
express	CD20	with	high	density	at	the	cell	surface	[17].	Pro-B	cells	and	antibody	producing	
plasma	cells	do	not	express	CD20,	and	are	therefore	not	vulnerable	to	CD20	targeting.	As	such,	
the	healthy	B	cell	pool	is	restored	after	rituximab	treatment	and	B	cell	immune	responses	are	
largely	preserved.	
Anti-CD20	mAbs	 have	 been	 classified	 as	 type	 I	 and	 type	 II	 [18],	which	 both	 induce	
ADCC.	 Type	 I	 mAbs	 (e.g.	 rituximab	 and	 ofatumumab)	 are	 regarded	 as	 the	 most	 potent	
antibodies	 because	 of	 their	 capacity	 to	 initiate	 CDC	 in	 contrast	 to	 type	 II	 mAbs	 (e.g.	
obinutuzumab).	Furthermore,	type	II	mAbs	may	induce	direct	cell	death	(Figure	1b),	although	
the	 exact	 mechanism	 remains	 to	 be	 elucidated.	 Upon	 type	 I	 mAb	 binding,	 CD20	 is	
redistributed	 to	 specific	 microdomains,	 including	 lipid	 rafts	 and	 tetraspanin-enriched	
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microdomains	(Box	1),	which	stimulates	clustering	of	the	antibody	Fc	regions	involved	in	CDC.	
Unfortunately,	Fc	receptor	polymorphisms	and	downregulation	of	CD20	caused	by	repeated	
exposure	 to	 rituximab	 [19]	 demonstrate	 the	 urgent	 need	 for	 development	 of	 alternative	
membrane-targeted	strategies.	
	
Emerging	membrane-targeted	therapies	for	B-cell	lymphoma	
Besides	 CD20,	 numerous	 other	 potential	 membrane	 targets	 have	 been	 investigated	 in	
lymphoma	including:	CD19,	CD22,	CD23,	CD37,	CD47,	CD52,	CD74,	CD79α,	CD80,	HLA-DR,	and	
the	BCR	(idiotype).	Furthermore,	immune	checkpoint	inhibitors	that	target	programmed	cell	
death	 protein	 1	 (PD-1)	 and	 programmed	 cell	 death	 ligand	 1	 (PD-L1)	 are	 currently	 in	 the	
spotlight	for	treatment	of	B-NHL.	Targeting	of	some	of	these	cell	surface	proteins	with	mAbs	
has	 shown	promising	 therapeutic	 efficacy,	 but	 targeting	others	 seems	 less	 suitable	due	 to	
limited	 specificity	 (e.g.	 CD80	 and	 HLA-DR	 are	 very	 broadly	 expressed)	 or	 resistance	
development	 (e.g.	 due	 to	 antigen	 shedding	 or	 internalization).	 A	 few	 new	mAbs	 directed	
against	B-cell	surface	proteins	currently	tested	in	clinical	trials	show	promising	results	either	
as	first-line	therapy	in	combination	with	rituximab,	or	as	monotherapy	for	heavily-pretreated	
B-NHL	 patients	 (e.g.	 anti-CD22:	 epratuzumab;	 anti-CD37:	 otlertuzumab;	 anti-CD74:	
milatuzumab)	(reviewed	in	[15]).	Future	antibody	engineering	studies,	including	conjugation	
to	radio/immunotoxins	or	generation	of	bispecific	antibodies,	may	further	improve	their	anti-
lymphoma	potency.	Below	we	will	discuss	recent	results	and	focus	on	novel	developments	in	
targeting	 membrane	 proteins	 in	 B-NHL,	 including	 immune	 checkpoints	 and	 tetraspanins	
(Figure	1).		
	
Aberrant	B-cell	receptor	function	in	B-NHL		
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The	BCR,	a	membrane-bound	immunoglobulin	(Ig),	can	be	divided	in	5	classes	(IgG,	IgD,	IgM,	
IgA	or	IgE)	that	are	important	for	antigen	recognition	and	initiation	of	signaling	events	leading	
to	B-cell	survival,	proliferation	and	migration	[20].	The	BCR	forms	a	complex	with	CD79α	(or	
Igα)	 and	CD79β	 (or	 Igβ)	which	both	 contain	 an	 immunoreceptor	 tyrosine-based	 activation	
motif	 (ITAM)	 to	 transmit	 intracellular	 signaling.	 Upon	 antigen	 binding,	 the	 conformational	
state	 of	 the	 BCR	 changes	 to	 initiate	 downstream	 signaling,	 but	 the	 underlying	 molecular	
mechanisms	 are	 still	 debated.	 The	 “conformation-induced	oligomerization	model”,	 which	
proposes	 that	 single	 BCRs	 oligomerize	 upon	 antigen	 recognition	 [21],	 has	 recently	 been	
challenged	 by	 super-resolution	 studies.	 This	 has	 led	 to	 convincing	 evidence	 for	 the	
“dissociation-activation	 model”,	 in	 which	 BCR	 oligomers	 dissociate	 upon	 antigen	 binding,	
gaining	an	open	conformation	[22,23].	This	conformational	change	influences	the	distribution	
of	BCR	co-receptors	CD19	and	CD20	that	interact	with	IgD	oligomers	on	resting	B	cells,	and	
relocate	 to	 IgM	oligomers	upon	B-cell	activation	 [23].	These	changes	 in	plasma	membrane	
organization	 are	 controlled	 by	 a	 superfamily	 of	 membrane-organizing	 proteins,	 called	
tetraspanins	 (Box	 2).	 Tetraspanin	 CD81	 is	 required	 for	 reorganization	 of	 CD19	 to	 BCR	
nanoclusters,	which	enables	binding	of	signaling	proteins	to	the	intracellular	domain	of	CD19	
and	initiation	of	signaling	downstream	of	the	BCR	[24,25].	
Two	modes	of	BCR	 signaling	have	been	described:	 1)	 active	 signaling	upon	antigen	
binding	to	the	BCR	leading	to	NF-κB	activation	via	Syk,	phosphoinositide	3-kinase	(PI3K)	and	
Bruton’s	 tyrosine	 kinase	 (BTK);	 and	 2)	 tonic	 signaling,	 an	 antigen-independent	mechanism	
required	for	B-cell	survival	which	occurs	in	mature	resting	B	cells	via	activation	of	PI3K	and	
protein	kinase	B	(AKT)	(reviewed	in	[26])	(Figure	1c).	In	most	GC-derived	B-cell	lymphomas,	
BCR	signaling	 is	disturbed	 resulting	 in	enhanced	B-cell	 survival	and	proliferation.	BL	 shows	
tonic	BCR	signaling	(Figure	1c)	via	constitutive	activation	of	the	PI3K	pathway	driven	by	MYC	
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translocation	to	the	IGH	locus	during	SHM	[5,27].	Chronic	active	BCR	signaling	is	seen	in	ABC-
DLBCL	 which	 is	 evidenced	 by	 knockdown	 experiments	 of	 BTK	 or	 components	 of	 the	 BCR	
complex	 that	 induced	 killing	 of	 lymphoma	 cells	 [4].	 In	 contrast,	GCB-DLBCL	 cells	were	not	
killed,	indicating	they	do	not	require	BCR	signaling	to	survive.	In	the	majority	of	ABC-DLBCL	
cases,	 self-antigens	 present	 in	 the	 tumor	 microenvironment	 may	 drive	 continuous	 BCR	
stimulation	(Figure	1c)	[28].	The	presence	of	BCR	clusters	on	ABC-DLBCL	cells	resembles	BCR	
clusters	observed	on	normal	B	cells	following	antigen	stimulation	[4].	 In	10%	of	ABC-DLBCL	
cases,	gain-of-function	mutations	in	CARMA1	(also	known	as	CARD11)	were	found	to	result	in	
continuous	NF-κB	activation	[29].	Furthermore,	in	20%	of	ABC-DLBCL	cases,	somatic	mutations	
in	the	CD79α/CD79β	ITAM	domains	induced	chronic	active	BCR	signaling	via	inhibition	of	BCR	
endocytosis	and	prevention	of	binding	of	Lyn	to	CD79β	[4].	
	In	FL,	constitutive	BCR	signaling	induced	by	presence	of	(self-)antigens	has	been	found	
in	only	 20-25%	of	 the	 cases	 [30,31],	whereas	 the	majority	of	 FL	 cases	 (80%)	bear	 somatic	
mutations	in	the	IgM-BCR	leading	to	increased	incorporation	of	N-glycosylation	sites	[32,33].	
If	this	occurs	in	the	antigen-binding	side	of	the	BCR	it	may	prevent	binding	of	(self-)antigens,	
but	in	turn	can	be	recognized	and	stimulated	by	lectin	receptors	on	myeloid	cells	in	the	tumor	
microenvironment	[34,35].	This	results	in	re-organization	of	the	BCR	complex	(including	CD19)	
into	signaling	platforms	and	persistent	antigen-independent	signaling	via	Syk	and	BTK.	
	 Currently,	different	small	molecule	inhibitors	targeting	signaling	proteins	downstream	
of	the	BCR	(Syk,	Lyn,	PI3K,	BTK)	are	under	investigation	as	novel	therapy	for	B-NHL	(reviewed	
in	 [26]).	 Still,	 increased	 understanding	 into	 the	 conformational	 changes	 in	 the	 BCR	 upon	
antigen	binding	may	open	new	opportunities	to	directly	target	the	BCR	itself.	This	idea	was	
originally	explored	in	the	1980’s,	in	which	treatment	of	lymphoma	patients	with	anti-idiotype	
antibodies	(targeting	the	variable	region	of	the	BCR)	revealed	promising	clinical	results	[36].	
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However,	 this	 approach	 required	 generation	 of	 patient-specific	 idiotype-antibodies	
hampering	clinical	implementation.	Recently,	a	new	tool	has	been	developed	to	screen	and	
target	tumor-specific	idiotypes	with	small	peptides	linked	to	a	pre-made	IgG-Fc	protein,	so-
called	anti-idiotype	peptibodies	[37],	which	directly	 induce	cell	death	via	BCR	signaling	and	
ADCC.	Furthermore,	 the	anti-CD79β	antibody-drug	conjugate	polatuzumab	vedotin	may	be	
promising	 to	 treat	 B-NHL	 patients	 [38],	 which	 is	 currently	 investigated	 in	 clinical	 trials	
(https://clinicaltrials.gov/).		
Therapeutic	 strategies	 targeting	 the	 BCR	 co-receptor	 CD19	 are	 encouraging	 for	
patients	with	relapsed/refractory	B-NHL.	CD19	chimeric-antigen	receptors	expressed	by	T	cells	
(CD19-CAR	T	 cells)	 consist	of	an	extracellular	domain	 specific	 for	CD19	on	B-NHL	cells	and	
intracellular	 domains	 to	 provide	 T	 cell	 stimulatory	 signals	 (e.g.	 CD3ζ	 and	 CD28).	 Adoptive	
transfer	of	CD19-CAR	T	cells	has	given	complete	responses	in	~50-60%	of	B-NHL	patients	in	
phase	I/II	clinical	trials	[39].	Furthermore,	blinatumomab,	a	CD19/CD3	bispecific	T-cell	engager	
(BiTE)	generated	from	the	antigen-binding	regions	of	the	single-chain	antibodies	of	CD19	and	
CD3,	is	approved	by	the	FDA	for	treatment	of	acute	lymphoblastic	leukemia	(ALL)	and	clinical	
results	are	currently	evaluated	 for	 treatment	of	other	B-cell	malignancies,	 including	B-NHL	
[40].	Future	research	is	required	to	determine	the	consequences	of	targeting	the	BCR	complex	
in	 B-NHL	 patients,	 and	 in	 particular	 how	 this	 changes	 BCR	 conformation	 and	 downstream	
signaling.	
	
Function	and	targeting	of	immune	checkpoints	PD-1/PD-L1	in	B-NHL	
Cancer	 immunotherapy	has	been	chosen	as	 the	scientific	breakthrough	of	2013	by	Science	
journal	 [41],	 due	 to	 promising	 results	 with	 immune	 checkpoint	 inhibitors.	 Immune	
checkpoints	are	proteins	that	regulate	immune	cell	activation	to	maintain	self-tolerance	and	
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prevent	 autoimmunity	 (reviewed	 in	 [42]).	 More	 specifically,	 these	 checkpoints	 play	 an	
important	 role	 in	 controlling	 T	 cell	 priming	 and	 activation.	 For	 example,	 PD-1	 on	 T	 cells	
transfers	an	inhibitory	signal	when	engaged	by	PD-L1	expressed	by	tumor	cells	or	activated	T	
cells.	
	 Tumor	cells	may	exploit	these	checkpoints	to	escape	or	suppress	the	immune	system	
by	(over-)expressing	PD-L1.	Currently,	anti-PD-1	mAbs	(pembrolizumab	and	nivolumab)	and	
anti-PD-L1	mAbs	(atezolizumab	and	durvalumab)	demonstrate	promising	clinical	results	in	the	
treatment	of	different	solid	tumors,	including	metastatic	melanoma,	urothelial	carcinoma	and	
advanced	non-small	cell	lung	carcinoma	(reviewed	in	[43]).	This	treatment	strategy	has	also	
gained	 more	 attention	 in	 the	 B-cell	 lymphoma	 field	 (Figure	 1d)	 (reviewed	 in	 [42]),	 and	
nivolumab	has	recently	been	approved	by	the	FDA	for	the	treatment	of	relapsed/refractory	
Hodgkin	lymphoma	due	to	promising	clinical	results	[44].	
For	 DLBCL,	 promising	 clinical	 results	 have	 been	 obtained	 with	 the	 anti-PD-1	mAbs	
pidilizumab	and	nivolumab	 [45,46],	 and	both	anti-PD-1	and	anti-PD-L1	mAbs	are	 currently	
tested	 in	 clinical	 trials	 (https://clinicaltrials.gov/).	 It	 has	been	 shown	 that	a	 subset	of	ABC-
DLBCL	tumors	(11-31%)	display	high	expression	of	PD-L1,	 in	contrast	to	GCB-DLBCL	tumors	
that	virtually	lack	expression	of	PD-L1.	This	high	PD-L1	expression	has	been	suggested	to	be	
involved	in	the	poorer	prognosis	of	ABC-DLBCL	patients	compared	to	patients	with	GCB-DLBCL	
[47,48].	Since	PD-L1	expression	is	restricted	to	a	minority	of	DLBCL	patients,	 it	 is	 likely	that	
only	this	group	will	benefit	from	immune	checkpoint	blockade	[48,49].	
	 Although	PD-L1	is	rarely	expressed	in	FL	cells	[42,47],	FL	patients	may	still	benefit	from	
immune	checkpoint	blockade,	since	inhibition	of	PD-1-expressing	tumor-infiltrating	T	cells	by	
PD-L1-expressing	non-tumor	cells	in	the	tumor	microenvironment	can	be	reversed	[50].	This	
has	been	supported	by	clinical	studies	demonstrating	good	responses	in	FL	patients	treated	
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with	anti-PD-1	mAbs	 (nivolumab	and	pidilizumab)	 [46,51].	Trials	with	pembrolizumab	 in	FL	
patients	are	currently	ongoing	(https://clinicaltrials.gov/).	Several	studies	have	reported	that	
BL	cells	do	not	express	PD-L1	[47,49],	and	PD-1/PD-L1	checkpoint	inhibitors	have	therefore	
not	yet	been	studied	in	BL.	Still,	the	promising	results	of	immune	checkpoint	inhibition	in	FL,	
which	rarely	expresses	PD-L1,	may	be	translated	to	BL.	Taken	together,	targeting	the	immune	
checkpoint	membrane	proteins	PD-1/PD-L1	seems	a	promising	novel	treatment	option	for	a	
selected	group	of	ABC-DLBCL	and	FL	patients.	However,	it	is	still	debated	whether	expression	
of	 PD-1/PD-L1	 is	 of	 prognostic	 value	 for	 immune	 checkpoint	 inhibition	 therapy	 in	 B-NHL	
[52,53].	
	
CD37	rediscovered	as	B-cell	membrane	target	in	the	treatment	of	B-NHL	
Tetraspanin	CD37	recently	regained	attention	as	promising	membrane	target	for	mature	B-
cell	malignancies	(Box	2).	CD37	expression	is	restricted	to	the	immune	system	with	highest	
abundance	 on	 mature	 B	 cells,	 and	 is	 absent	 in	 earlier	 stages	 of	 B-cell	 development	 and	
decreased	on	plasma	cells	[54,55].	This	pattern	is	also	reflected	in	different	B-cell	lymphomas:	
CD37	is	mostly	expressed	on	B-cell	malignancies	derived	from	mature	B	cells	(although	~50%	
of	 DLBCL	 patients	 lack	 CD37	 [56,57],	 discussed	 below),	 but	 not	 in	 acute	 lymphoblastic	
lymphoma	and	multiple	myeloma	[58].	Comparable	to	CD20,	this	distinct	expression	pattern	
makes	CD37	an	interesting	target	in	GC-derived	B-cell	lymphomas.	Already	in	1989,	the	first	
CD37-targeting	antibody	(labeled	with	the	radioactive	 isotope	iodine	131)	was	tested	in	10	
refractory	NHL	patients	with	promising	clinical	results	[59].	However,	as	anti-CD20	treatment	
(rituximab)	was	introduced	at	the	same	time,	anti-CD37	therapy	was	forgotten	for	almost	two	
decades,	 until	 the	 development	 of	 a	 novel	 CD37-targeting	 mAb-derived	 polypeptide	 re-
established	the	interest	in	this	target	[60].		
11	
	
Nowadays	 several	 different	 antibody-based	 CD37-targeting	 approaches	 are	 under	
investigation	in	phase	I	and	II	trials	for	chronic	lymphocytic	leukemia	(CLL)	and	refractory	or	
relapsed	 NHL	 patients	 (reviewed	 in	 [61]	 and	 see	 https://clinicaltrials.gov/)	 (Figure	 1e).	
Otlertuzumab	(TRU-016),	a	humanized,	antibody-derived	CD37-targeting	peptide,	is	closest	to	
general	clinical	application	in	B-cell	malignancies.	In	a	randomized	phase	II	study,	relapsed	CLL	
patients	 treated	 with	 the	 chemotherapeutic	 bendamustine	 plus	 otlertuzumab	 showed	
increased	progression	free	survival	compared	to	patients	treated	with	bendamustine	alone	
[62].	
The	anti-tumor	mechanisms	by	which	anti-CD37	agents	 act	 include	ADCC,	CDC	and	
direct	apoptosis	signaling	[60,63,64].	Additionally,	CD37-antibody	complexes	are	known	to	be	
internalized,	which	 has	 led	 to	 the	 generation	 of	 novel	 anti-CD37	 agents	 coupled	 to	 toxins	
(IMGN529,	 an	 anti-CD37	 antibody	 conjugated	 to	 an	 anti-microtubule	 agent)	 [64]	 and	
radioactive	 labels	 (177Lu-tetulomab)	 [65].	 Both	 agents	 showed	 promising	 results	 in	 NHL	
xenograft	mouse	models	 [64,65].	Moreover,	 177Lu-tetulomab	was	 internalized	with	 higher	
efficiency	 than	 177Lu-rituximab	 complexes	 in	 vitro	 [65],	 and	 IMGN529	 showed	 increased	
activity	compared	to	rituximab	or	CVP	chemotherapy	in	a	FL-derived	xenograft	mouse	model	
[64].	A	phase	I	clinical	trial	completed	in	July	2016	studied	IMGN529	in	relapsed/refractory	
NHL	 and	 CLL	 patients	 (NCT01534715),	 and	 several	 phase	 I/II	 clinical	 studies	 to	 test	 177Lu-
tetulomab	(Betalutin)	are	currently	including	NHL	patients	(https://clinicaltrials.gov/).	
Furthermore,	new	 insights	 into	the	function	of	CD37	have	prompted	the	 interest	 in	
combination	 strategies.	 CD37	 is	 important	 for	 the	 survival	 of	 IgG1-secreting	 plasma	 cells	
through	the	membrane	organization	of	α4β1	integrins,	and	subsequent	activation	of	the	AKT	
signaling	pathway	[66].	The	intracellular	tails	of	CD37	can	be	tyrosine	phosphorylated,	leading	
to	 the	 initiation	 of	 apoptotic	 signaling	 via	 the	 N-terminal	 immunoreceptor	 tyrosine-based	
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inhibition	motif	 (ITIM)-like	 domain,	 and	opposite	 survival	 signaling	 via	 its	 C-terminal	 ITAM	
domain	 [63].	 Both	 pathways	 are	 induced	 by	 the	 CD37-targeting	mAb-derived	 polypeptide	
SMIP-016,	which	was	the	basis	for	development	of	TRU-016.	Although	signaling	to	apoptosis	
is	the	most	prominent,	the	efficiency	of	CD37	targeting	could	be	improved	using	combination	
therapy	with	pro-survival	PI3K	inhibitors	[63].	
Importantly,	recent	studies	revealed	that	~50%	of	DLBCL	tumors	are	negative	for	CD37	
expression,	and	its	loss	is	a	potential	risk	factor	for	R-CHOP	resistance	and	poor	survival	rates	
independent	of	 the	 International	Prognostic	 Index	 (IPI)	 [56,57].	The	underlying	mechanism	
involves	enhanced	activation	of	the	IL-6	signaling	pathway	in	CD37-negative	lymphomas	[56].	
IL-6	 is	known	to	be	 involved	 in	 the	development	of	many	cancers,	 including	hematological	
malignancies,	and	several	IL-6	targeting	strategies	have	been	developed	(reviewed	in	[67,68]).	
Based	on	these	studies,	inhibition	of	IL-6	signaling	(using	mAb	anti-IL-6	siltuximab	or	anti-IL-
6R	tocilizumab)	may	represent	a	potential	new	treatment	strategy	 for	patients	with	CD37-
negative	DLBCL	(Figure	1e).	
	
Dynamic	protein	interactions	shape	the	organization	of	the	B-cell	membrane	
Proteins	in	the	plasma	membrane	are	not	randomly	distributed,	but	instead	they	are	localized	
to	specific	microdomains	(Box	1).	One	of	the	first	models	of	membrane	protein	organization	
on	the	B-cell	membrane	was	published	two	decades	ago	[69].	Using	flow	cytometry	energy	
transfer	(FCET)	experiments,	it	was	shown	that	CD20	interacts	with	tetraspanins	CD53,	CD81,	
CD82	 on	 a	 lymphoma	 B-cell	 line.	 In	 addition,	 confocal	 microscopy	 [70]	 and	 co-
immunoprecipitation	 experiments	 [71]	 revealed	 that	 CD20	 also	 clusters	 with	 the	 BCR	 in	
specialized	 microdomains,	 indicating	 that	 they	 are	 localized	 in	 lipid	 rafts	 or	 tetraspanin	
microdomains	(Box	1).	The	BCR	dissociates	from	CD20	to	distinct	lipid	rafts	upon	stimulation,	
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and	 is	 subsequently	 internalized	 [70].	A	direct	 interaction	between	CD20	and	the	BCR	was	
recently	 confirmed	using	 proximity-ligation	 assay	 [23].	 It	was	 shown	 that	 CD20	 (similar	 to	
CD19)	interacts	with	different	BCR	classes	(IgD/IgM)	on	resting	and	antigen-activated	human	
B	cells,	demonstrating	redistribution	of	CD20	upon	BCR	stimulation.		
CD20	has	been	shown	to	interact	with	several	tetraspanins	(CD53,	CD81,	CD82)	[69],	
although	 CD37	 was	 not	 studied.	 Recently,	 we	 discovered	 that	 both	 protein	 and	 mRNA	
expression	of	CD20	and	CD37	on	lymphoma	B	cells	are	correlated	[57].	Although	this	is	in	line	
with	 the	 inferior	 outcome	 of	 CD37-negative	 DLBCL	 patients	 upon	 R-CHOP	 therapy,	 the	
prognostic	 significance	 of	 CD37	 seems	 independent	 of	 CD20	 mRNA	 levels	 [57].	 Further	
research	is	necessary	to	verify	a	possible	direct	interaction	and	co-expression	patterns	of	CD37	
and	CD20	in	B-NHL	cases.	
	 These	 studies	 indicate	 that	 the	 organization	 of	 the	 B-cell	 membrane	 is	 shaped	 by	
dynamic	protein-protein	interactions	that	are	subject	to	change	upon	B-cell	activation.	This	
protein	 organization	 is	 not	 only	 important	 for	 B-cell	 function	 but	 also	 for	 the	 efficacy	 of	
membrane-targeted	 therapies,	 as	 illustrated	by	 clustering	of	CD20	upon	 rituximab	binding	
[18].	 Likewise,	 CD37-targeting	using	 SMIP-016	 resulted	 in	 translocation	 into	microdomains	
which	was	required	for	efficient	tumor	cell	apoptosis	[63].	On	lymphoma	B	cells,	changes	in	
membrane	 protein	 expression	 (e.g.	 absence	 of	 CD37)	 or	 protein	 clustering	 (e.g.	
conformational	 changes	of	 the	BCR	upon	binding	of	 self-antigens),	will	 change	 the	protein	
organization	and	interactions	at	the	plasma	membrane.	Based	on	these	studies	we	propose	
that	the	changed	cell	surface	protein	landscape	of	lymphoma	B	cells	has	consequences	for	the	
efficacy	 and	 application	 of	 membrane-targeted	 therapies	 (Figure	 2).	 Moreover,	 targeted	
therapies	 may	 alter	 dynamic	 protein-protein	 interactions	 affecting	 plasma	 membrane	
organization	and	downstream	signaling.	
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Concluding	remarks		
Many	 patients	 with	 B-NHL	 still	 face	 treatment	 failure	 or	 relapse	 upon	 standard	 therapy	
emphasizing	the	urgent	need	for	new	treatment	options.	The	plasma	membrane	is	the	most	
easily	accessible	part	of	the	tumor	cell,	and	exposes	a	variety	of	different	proteins	which	may	
serve	 as	 treatment	 target.	 Here,	 we	 discussed	 the	widely	 studied	 target	 CD20,	 and	 three	
alternative	membrane	targets	(BCR,	PD-L1	and	CD37)	that	are	currently	under	investigation	in	
clinical	trials	to	treat	B-NHL.	Furthermore,	patients	with	CD37-negative	lymphoma	B	cells	have	
a	dismal	prognosis	and	may	benefit	from	anti-IL-6(R)-targeted	therapy.	
	 Membrane	 proteins	 interact	 with	 each	 other	 and	 thereby	 facilitate	 various	 cell	
biological	processes,	including	initiation	of	downstream	signaling.	B-cell	activation	will	affect	
these	 protein	 interactions	 through	 induction	 of	 new	 interactions,	 more	 clustering,	 or	
alternatively	by	preventing	specific	interactions.	Evidence	is	accumulating	that	lymphoma	B	
cells	contain	aberrant	cell	surface	protein	expression	and	organization	which	has	important	
consequences	 for	both	application	and	outcome	of	membrane-targeted	 therapy	 for	B-NHL	
patients.		
We	are	only	at	the	beginning	of	understanding	membrane	organization	of	normal	and	
malignant	B	cells	and	further	research	is	required	to	address	the	outstanding	questions	in	this	
new	and	exciting	field	(see	Outstanding	Questions).	In	particular,	recent	advances	in	super-
resolution	microscopy	enables	imaging	the	membrane	composition	of	lymphoma	cells	at	the	
nanoscale	 level	 [72].	 Taking	 into	 account	 that	 lymphomas	 are	 heterogeneous	 tumors	 [2],	
targeting	membrane	proteins	as	monotherapy	will	probably	not	be	sufficient	 for	complete	
tumor	eradication.	Thus,	the	use	of	combination	therapies,	like	immuno-chemotherapy	and	
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the	additional	use	of	small	molecule	inhibitors,	will	be	important	in	the	future	treatment	of	B-
cell	non-Hodgkin	lymphoma.	
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Figure	 1.	 Current	 and	 novel	 membrane-targeted	 therapies	 in	 B-cell	 lymphoma.	 (a)	
Membrane	proteins	used	in	and	explored	for	lymphoma-targeted	therapy.	Left	to	right:	CD20;	
BCR	with	 its	signaling	proteins	CD79α/β;	CD19;	PD-L1;	tetraspanin	CD37	with	the	IL-6R.	(b)	
Targeting	CD20	using	mAb	 (e.g.	 rituximab)	will	 cluster	CD20	proteins	 leading	 to	 tumor	cell	
death	via	CDC,	ADCC	and/or	direct	apoptosis.	(c)	In	chronic	active	BCR	signaling	(i),	binding	of	
(self-)antigens	 to	 the	 BCR	 triggers	 recruitment	 of	 Syk	 to	 the	 phosphorylated	 (p-)ITAMs	 of	
CD79α/β,	which	leads	to	translocation	of	PI3K	to	CD19.	Subsequently,	BTK	is	activated	which	
initiates	NF-κB	activation	via	the	CARMA1-BCL10-MALT1	complex	resulting	 in	 lymphoma	B-
cell	 survival.	 In	 tonic	 BCR	 signaling	 (ii),	 constitutive	 activation	of	 PI3K	 in	 absence	of	 (self-)	
antigens	results	in	continuous	signaling	via	AKT	pathway	and	lymphoma	cell	survival.	Novel	
anti-idiotype	therapy	strategies	can	directly	target	the	BCR.	Syk,	PI3K	and	BTK	can	be	inhibited	
using	 small	 molecule	 inhibitors	 (*).	 (d)	 Immune	 checkpoint	 inhibitors	 (e.g.	 nivolumab,	
pembrolizumab,	pidilimumab)	bind	to	PD-L1	expressed	on	lymphoma	B	cells	or	to	PD-1	on	T	
cells.	This	inhibits	the	immune-escape	mechanism	used	by	ABC-DLBCL	and	FL	cells.	(e)	In	CD37-
expressing	(CD37+)	B-cell	lymphoma	(i),	tumor	cell	death	can	be	induced	by	targeting	CD37-
specific	mAbs	(IMGN529,	Otlertuzumab).	In	contrast,	CD37-negative	(CD37-)	B-cell	lymphoma	
(~50%	 of	 DLBCL	 cases)	 (ii),	 shows	 constitutive	 activation	 of	 the	 IL-6	 signaling	 pathway	
(increased	p-AKT	and	p-STAT3).	These	patients	may	benefit	from	α-IL-6(R)	therapy.	
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Figure	2.	Plasma	membrane	organization	of	 lymphoma	B	cells	determines	the	efficacy	of	
membrane-targeted	 therapies.	 The	 cell	 membrane	 (light	 area)	 is	 highly	 organized	 into	
specialized	microdomains	(dark	area)	that	are	formed	by	dynamic	homotypic	(e.g.	CD20-CD20)	
and	heterotypic	(e.g.	CD19-CD81)	protein-protein	interactions.	Upon	ligand-receptor	binding	
(e.g.	IL-6	to	IL-6R),	induction	of	a	conformational	change	can	lead	to	rearrangement	of	protein-
protein	interactions	and	reorganization	of	the	membrane	landscape.	Lymphoma	B	cells	have	
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a	disrupted	membrane	protein	organization,	e.g.	due	to	constant	activation	of	the	BCR	by	(self-
)antigens,	overexpression	of	PD-L1,	or	 loss	of	tetraspanin	CD37.	 In	addition,	BCR	activation	
results	 in	 CD20	 dissociation	 and	 redistribution,	 and	 anti-CD20	 targeted	 therapy	 using	
rituximab	 induces	CD20	clustering.	These	data	support	a	model	 in	which	 the	microdomain	
organization	 of	 lymphoma	 cells	 determines	 the	 efficacy	 of	membrane-targeted	 therapies,	
which	has	important	implications	for	treatment	application	and	clinical	outcome.	
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Box	1.	Plasma	membrane	microdomains	
The	plasma	membrane	 is	 composed	of	multiple	different	proteins	and	 lipids	 that	are	non-
randomly	 localized	 into	 specialized	 areas	 (microdomains).	 Signaling	 molecules,	 lipids	 and	
proteins	can	cluster	together	in	such	organized	domains,	which	is	crucial	for	efficient	signal	
transduction	[73,74].	Disrupting	membrane	organization	interferes	with	several	membrane-
proximal	signaling	processes,	 including	those	involved	in	tumor	cell	survival	and	metastasis	
(reviewed	in	[73]).	Different	types	of	membrane	microdomains	have	been	reported,	including	
lipid	 rafts	 and	 tetraspanin-enriched	 microdomains	 (TEMs)	 [75].	 Lipid	 rafts	 were	 originally	
identified	as	membrane	fractions	that	are	insoluble	in	the	strong	detergent	Triton	X-100	[76],	
hence	 they	 are	 also	 defined	 as	 detergent-resistant	membrane	 domains	 (DRMs).	 They	 are	
enriched	 in	 densely	 packed	 sphingolipids	 and	 cholesterol,	 and	 harbor	
glycophosphatidylinositol	 (GPI)-anchored	 proteins	 among	 others	 [77].	 A	 different	 type	 of	
microdomain	is	formed	by	tetraspanin	proteins	(Box	2)	that	associate	with	themselves	and	
with	specific	partner	molecules	(including	CD20,	integrins	and	MHCII)	in	clusters	known	as	the	
tetraspanin	web	or	TEMs	[78–80].	Although	both	TEMs	and	lipid	rafts	are	detergent-resistant	
and	present	in	DRMs,	they	are	very	different	domains	in	terms	of	protein	composition	[81,82].	
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Box	2.	Tetraspanins	in	cancer	development		
Tetraspanins	 are	 a	 family	 of	 four-transmembrane	 proteins	 involved	 in	 plasma	membrane	
organization	[79,82].	The	mammalian	tetraspanin	superfamily	consists	of	33	members,	which	
are	expressed	on	almost	all	cells	and	tissues	[83].	Tetraspanins	consist	of	four	transmembrane	
domains,	 a	 short	 extracellular	 loop	 (EC1),	 a	 large	 extracellular	 loop	 (EC2)	 containing	 a	
conserved	CCG	region,	a	small	intracellular	loop	and	two	short	intracellular	tails	[84],	and	S.	
van	Deventer	 et	 al.,	 in	 press].	Despite	 its	 similar	 structure,	 CD20	 cannot	be	 classified	 as	 a	
genuine	tetraspanin	protein,	since	it	lacks	the	conserved	CCG	region	in	the	large	extracellular	
loop	[85].	The	EC2	and	transmembrane	domains	are	involved	in	the	formation	of	tetraspanin-
enriched	microdomains	 (TEMs)	 by	 lateral	 associations	 with	 interaction	 partners,	 including	
other	 tetraspanins	 and	 integrins	 [78–80].	 Their	 short	 intracellular	 tails	 can	 interact	 with	
cytosolic	signaling	molecules	(e.g.	PKC,	Pi4K,	Rac)	[63,79],	and	S.	van	Deventer	et	al.,	in	press].	
Through	 their	multiple	 interaction	 partners,	 tetraspanins	 are	 involved	 in	 different	 cellular	
processes	 including	 survival,	 proliferation,	 adhesion	 and	 migration	 [78].	 Recently,	 several	
studies	have	shown	that	tetraspanins	contribute	to	cancer	development	and	metastasis,	and	
tetraspanin	 expression	 has	 been	 associated	 with	 patient	 outcome	 [56,86].	 Therefore,	
tetraspanins	 are	 interesting	 targets	 for	 cancer	 therapy,	 and	 different	 (pre-)clinical	 studies	
using	 tetraspanin	 targeting	 strategies	 are	 currently	 ongoing	 (https://clinicaltrials.gov/)	
[61,86].	
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Glossary	
Antibody-dependent	 cell-mediated	 cytotoxicity:	 Induction	 of	 cell	 death	 via	 binding	 of	 an	
antibody	to	its	cell	surface	target.	The	Fc	tail	of	the	antibody	engages	Fc	receptor-expressing	
immune	 cells,	 like	NK	 cells	 and	macrophages,	 that	will	 kill	 the	 antibody-bound	 target	 (i.e.	
tumor)	cell.	
Burkitt	 lymphoma:	An	 aggressive	 type	 of	 B	 cell	 non-Hodgkin	 lymphoma	 characterized	 by	
deregulation	of	the	MYC	proto-oncogene.		
CHOP:	Abbreviation	for	Cyclophosphamide	–	Doxorubicin	(Hydroxydaunorubicin)	–	Vincristine	
(Oncovin)	 –	 Prednisone.	A	 chemotherapy	 cocktail	mostly	 used	 to	 treat	 B-cell	 non-Hodgkin	
lymphoma	patients.	Often	used	in	combination	with	anti-CD20	mAb	rituximab	(R-CHOP).	
Class	 switch	 recombination:	 The	process	 in	which	 the	 isotype	or	 class	 of	 immunoglobulin	
produced	by	the	B	cell	is	switched;	e.g.	from	IgM	to	IgG.	This	occurs	via	genomic	changes	in	
the	constant	region	of	the	immunoglobulin	heavy	chain.	
Complement-dependent	 cytotoxicity:	 Induction	 of	 cell	 death	 via	 activation	 of	 the	
complement	system	(C1q	binding	to	the	antibody),	which	will	lyse	the	target	(i.e.	tumor)	cell	
membrane.	
CVP:	Abbreviation	for	Cyclophosphamide	–	Vincristine	–	Prednisone.	A	chemotherapy	cocktail	
used	to	treat	follicular	lymphoma	patients.		
Diffuse	large	B	cell	 lymphoma:	The	most	common	and	most	aggressive	type	of	B-cell	non-
Hodgkin	 lymphoma,	 accounting	 for	 approximately	one	 third	of	 all	 non-Hodgkin	 lymphoma	
cases.		
Follicular	 lymphoma:	 The	 second	most	 common	 B-cell	 non-Hodgkin	 lymphoma.	 Follicular	
lymphoma	is	an	indolent	cancer,	but	can	transform	into	the	more	aggressive	DLBCL.		
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Germinal	 center:	 area	 in	 the	 B-cell	 follicles	 of	 secondary	 lymphoid	 tissues	 where	 B-cell	
proliferation,	class	switch	recombination,	somatic	hypermutation	and	selection	take	place.		
Somatic	hypermutation:	The	process	in	which	the	immunoglobulin-encoded	DNA	of	mature	
B	cells	is	subjected	to	the	introduction	of	random	point	mutations.	These	modifications	occur	
in	the	variable	region	of	the	immunoglobulin	gene	resulting	in	affinity	maturation	(increased	
affinity	BCR).	
